Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023473 (chronic myeloid leukemia)
 18,916 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Chronic myelogenous leukemia (CML) is a pluripotent stem cell malignancy with an incidence of 1.3 per 100,000. Occasionally this uncommon disease occurs concomitantly with other neoplasia including various lymphoproliferative disorders. Its association with solid tumors, especially in young people, is decidedly rare. We report the simultaneous occurrence of CML and signet-ringed adenocarcinoma of the rectum in a 20-year-old male. A review of the literature pertinent to this topic will be briefly discussed, emphasizing characteristics of rectal carcinomas in younger age-groups as well as the unexpected association of CML with solid tumors.
 ...
PMID:Simultaneous occurrence of chronic myelogenous leukemia and signet-ringed adenocarcinoma of the rectum. A case report with a review of the literature. 817 32

We investigated the incidence of post-transplant solid tumors in a cohort of 109 patients who had undergone auto-peripheral blood stem cell transplantation (PBSCT) for acute myelogenous leukemia (n = 18), acute lymphoblastic leukemia (n = 7), non-Hodgkin's lymphoma (n = 52), Hodgkin's disease (n = 5), multiple myeloma (n = 16), chronic myelogenous leukemia (n = 1), myelodysplastic syndrome (n = 3) and solid tumors (n = 7). The patients were followed up for a median of 32 months after PBSCT. Five second solid malignancies developed in 4 patients within 14 to 43 months after PBSCT: large cell carcinoma of the lung, adenocarcinoma of the rectum, cholangiocellular carcinoma of the liver, squamous cell carcinoma of the mouth, and adenocarcinoma of the gallbladder. The affected patients were 3 of 52 with non-Hodgkin's lymphoma and one of 16 with multiple myeloma. One of the patients was in the 5th decade of life (n = 31) and 3 were in the 6th decade (n = 31). The cumulative actuarial risk for developing post-transplant solid tumors was 8% at 8 years. Elderly patients (> or = 60 year old) who have undergone PBSCT need to be observed carefully for second neoplasms because of their increased risk of post-transplant solid tumors.
 ...
PMID:[Secondary solid tumors in autologous-peripheral blood stem cell transplantation recipients]. 1102 Sep 88